微质调节作为阿尔茨海默病的治疗策略:专注于微质预先调节方法
Younes Yassaghi1, Yasaman Nazerian1, Mobina Ghasemi1
1School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Journal of cellular and molecular medicine
|August 5, 2024
概括
微质预调可能为阿尔茨海默病 (AD) 管理提供一种新的策略. 这种方法旨在增强有益的M2微质活性,可能减缓疾病进展,改善阿兹海默症患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是记忆障碍.
- 关键的病理特征包括粉样β (Aβ) 沉积和神经纤维状结 (NFT).
- 神经炎症是由激活的微质细胞驱动的,在AD病变发生过程中起着重要作用.
研究的目的:
- 审查阿尔茨海默病的微质预制方法.
- 探索M2-激活的微质在神经保护和AD管理中的潜力.
- 研究调节微质活动的策略,以对抗AD的进展.
主要方法:
- 对阿尔茨海默病中微质激活研究的文献综述.
- 对M2微质表型及其抗炎作用的研究分析.
- 对微质细胞应用的预条件化策略的检查.
主要成果:
- 微质细胞,大脑的免疫细胞,在AD中被激活,导致炎症.
- M2激活的微质细胞具有抗炎和神经保护性质.
- 预先调节方法在调节微质功能以获得治疗效益方面表现有前途.
结论:
- 微质预制是阿尔茨海默病的潜在治疗途径.
- 增强M2微质活动可以减轻AD中的神经炎症和神经退行.
- 进一步研究微质预条件化策略对于AD治疗开发是有必要的.
相关概念视频
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456